TABLE 3.

Multivariable Logistic Regression Analysis to Investigate Characteristics Associated With Chemotherapy Received Among Patients With Stage I Breast Cancer Diagnosed Between 2006 and 2009 and Treated Off the Clinical Trial

	HER2 Positive				HER2 Negative
	Intensive Versus Non-intensive N=289		TCH Versus ACTH N=210		Intensive Versus Non-intensive N=753		TC Versus AC N=447
Outcome	OR	95% CI	OR	95% CI	OR	95% CI	OR	95% CI
Age at diagnosis, y	0.98	0.95-1.01	1.02	0.99-1.06	0.95	0.93-0.97	1.03	1.01-1.06
HR positive (vs negative)	0.67	0.34-1.33	1.01	0.49-2.09	0.25	0.16-0.37	0.78	0.40-1.54
Tumor size, cm	2.03	1.04-3.96	0.25	0.12-0.51	2.57	1.67-3.94	1.12	0.60-2.11
Race/ethnicity (other vs non-Hispanic white)	0.53	0.25-1.15	1.25	0.55-2.84	1.30	0.86-1.96	1.56	0.77-3.17
Comorbidity score (≥1 vs 0)	0.65	0.31-1.37	1.94	0.85-4.42	1.09	0.71-1.67	1.25	0.64-2.45
Year of diagnosis	1.43	1.06-1.92	1.83	1.34-2.51	1.34	1.15-1.56	3.53	2.71-4.59
High grade (yes vs no)	1.22	0.62-2.40	2.87	1.34-6.13	1.88	1.26-2.81	0.76	0.42-1.36
Lymphovascular invasion (yes vs no)	1.47	0.63-3.41	0.92	0.38-2.24	2.05	1.30-3.23	0.98	0.48-2.00
Center
A	1.00		1.00		1.00		1.00
B	0.05	0.01-0.32	0.29	0.04-1.93	0.25	0.10-0.61	0.15	0.04-0.54
C	0.65	0.11-3.97	0.30	0.07-1.28	1.00	0.42-2.35	1.93	0.48-7.77
D	1.10	0.20-6.12	0.70	0.20-2.41	1.55	0.75-3.21	0.20	0.06-0.67
E	0.09	0.01-0.62	0.14	0.01-1.70	1.11	0.46-2.66	2.36	0.51-10.8
F	0.12	0.02-0.64	1.01	0.21-4.95	0.90	0.36-2.29	0.52	0.12-2.18
G	0.11	0.02-0.63	1.32	0.31-5.57	0.17	0.06-0.46	0.07	0.02-0.29
H	0.20	0.03-1.46	0.78	0.12-5.01	0.25	0.10-0.64	1.11	0.29-4.20

Abbreviations: 95% CI, 95% confidence interval; AC, doxorubicin and cyclophosphamide; ACTH, doxorubicin, cyclophosphamide, paclitaxel, and trastuzumab; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; OR, odds ratio; TC, docetaxel and cyclophosphamide; TCH, docetaxel, carboplatin, and trastuzumab.